Findings of Scientific Misconduct, 42575-42576 [E8-16741]
Download as PDF
Federal Register / Vol. 73, No. 141 / Tuesday, July 22, 2008 / Notices
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Additional information on all bank
holding companies may be obtained
from the National Information Center
website at www.ffiec.gov/nic/.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than August 15,
2008.
A. Federal Reserve Bank of Boston
(Richard Walker, Community Affairs
Officer) P.O. Box 55882, Boston,
Massachusetts 02106–2204:
1. WebFive, MHC and WebFive
Financial Services, Inc., both of
Webster, Massachusetts, to become bank
holding companies by acquiring
Webster Five Cents Savings Bank,
Webster, Massachusetts.
Board of Governors of the Federal Reserve
System, July 17, 2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc.E8–16718 Filed 7–21–08; 8:45 am]
BILLING CODE 6210–01–S?≤
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
sroberts on PROD1PC70 with NOTICES
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Roxana Gonzalez, Carnegie Mellon
University: Based on reports submitted
by Carnegie Mellon University’s (CMU)
inquiry and investigation committees,
the Respondent’s own admission in
sworn testimony, and additional
analysis conducted by the Office of
Research Integrity (ORI) during its
VerDate Aug<31>2005
19:47 Jul 21, 2008
Jkt 214001
oversight review, the U.S. Public Health
Service (PHS) found that Roxana
Gonzalez, graduate student, Department
of Social and Decision Sciences and
Psychology, CMU, engaged in scientific
misconduct in research supported by
National Institute of Mental Health
(NIMH), National Institutes of Health
(NIH), grants R01 MH56880, R03
MH62376, and R24 MH67346.
Specifically, PHS found that Ms.
Gonzalez engaged in the following acts
of scientific misconduct:
1. Respondent altered the main
dependent variable (life events; life
expectation) in the electronic file and
the manipulation check variables for
ease-of-thought generation so that the
reported study results are largely
unsupported in:
(a) Publication: Lerner, J.S., &
Gonzalez, R.M. ‘‘Forecasting one’s
future based on fleeting subjective
experiences.’’ Personality and Social
Psychology Bulletin 31:454–466, 2005;
(b) 2005 Manuscript: Lerner, J. S., &
Gonzalez, R. M. ‘‘On perceiving the self
as triumphant when happy or angry’’;
(c) Review Article: Lerner J. S.,
Tiedens, L.Z., & Gonzalez, R. M.
‘‘Portrait of the angry decision maker:
How appraisal tendencies shape anger’s
influence on cognition.’’ Journal of
Behavioral Decision Making: Special
Issue on Emotion and Decision Making.
2. Respondent falsified cortisol
values, and possibly cardiovascular
measures and optimistic appraisals (as
measured by LOT), so that a large
portion of the mediation analyses of
Table 3 does not reflect the data actually
collected and analyzed for the study
reported in a publication (Lerner, J.S.,
Gonzalez, R.M., Dahl, R.E., Hariri, A.R.,
& Taylor, S.E. ‘‘Facial expressions of
emotion reveal neuroendocrine and
cardiovascular stress responses.’’
Biological Psychiatry 58:743–750, 2005).
Respondent further allowed one of her
collaborators to report the results from
this study at the Annual Meeting of the
American Psychological Society held in
Los Angeles, California in May 2005,
although Respondent’s collaborator did
not know at the time that the results
were tainted by Respondent’s acts of
research misconduct.
3. Respondent falsified the analyses
based on participants’ responses to the
manipulation check items (including
the data for self reported fear) in a study
reported in a publication (Fischhoff, B.,
Gonzalez, R.M., Lerner, J.S., & Small,
D.A. ‘‘Evolving judgments of terrorism’s
risks: Foresight, hindsight, and
emotion.’’ Journal of Experimental
Psychology: Applied 11:124–139, 2005.
4. Respondent falsified the main
dependent variable (reservation price,
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
42575
BDM) in the electronic file for 48 of the
175 subjects participating in a study
reported in a 2005 manuscript (Lerner,
J.S., Gonzalez, R.M., Small, D.A.,
Lowenstein, G., & Dahl, R.E. ‘‘Emotional
influence on economic behavior among
adolescents.’’). Respondent directed the
alteration of the paper files for those
subjects in order to match the altered
electronic file. One of Respondent’s
collaborators included a qualitative
description of the results of the research
that is the subject of this study in an
NIH grant application, although
Respondent’s collaborator did not know
at the time that the results were tainted
by the Respondent’s acts of research
misconduct.
ORI acknowledges Ms. Gonzalez’
extensive cooperation with CMU’s
research misconduct proceedings.
Ms. Gonzalez has entered into a
Voluntary Exclusion Agreement
(Agreement) in which she has
voluntarily agreed, beginning on June
26, 2008:
(1) To exclude herself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant or
contractor to PHS, for a period of three
(3) years;
(2) That for a period of three (3) years,
any institution that submits an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
or that uses the Respondent in any
capacity on PHS supported research, or
that submits a report of PHS-funded
research in which the Respondent is
involved, must concurrently submit a
plan for supervision of the Respondent’s
duties to the funding agency for
approval; the supervisory plan must be
designed to ensure the scientific
integrity of the respondent’s research
contribution; Respondent agrees to
ensure that a copy of the supervisory
plan is also submitted to ORI by the
institution; Respondent agrees that she
will not participate in any PHSsupported research until such a
supervisory plan is submitted to ORI;
(3) for a period of three (3) years to
ensure that any institution employing
her submits, in conjunction with each
application for PHS funds or report,
manuscript, or abstract of PHS-funded
research in which the Respondent is
involved, a certification that the data
provided by the Respondent are based
on actual experiments or are otherwise
legitimately derived, and that the data,
procedures, analyses, and methodology
are accurately reported in the
application, report, manuscript or
abstract; the Respondent must ensure
E:\FR\FM\22JYN1.SGM
22JYN1
42576
Federal Register / Vol. 73, No. 141 / Tuesday, July 22, 2008 / Notices
that the institution sends a copy of the
certification to ORI; and
(4) to write ORI-approved letters to (a)
collaborators/coauthors of the
manuscripts and published papers cited
above, stating what she falsified/
fabricated and offering restitution; and
(b) editors of the journals in which
papers were published (even if they
have been retracted/corrected) to state
that her falsifications/fabrications were
the underlying reason for the retraction/
correction.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E8–16741 Filed 7–21–08; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Preparedness
and Emergency Response Research
Centers: A Public Health System
Approach-Secondary Review
Committee (SRC), Program
Announcement Number (PA) TP 08–
001
sroberts on PROD1PC70 with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
Time and Date: 8:30 a.m.–5 p.m., August
7, 2008 (Closed).
Place: CDC, Global Communication Center,
1600 Clifton Road, NE., Atlanta, GA 30333,
(404) 639–3995.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of applications received in
response to ‘‘Preparedness and Emergency
Response Research Centers: A Public Health
System Approach-SRC,’’ PA TP 08–001.
For Further Information Contact: Daniel M.
Sosin, M.D., M.P.H., Senior Advisor for
Science, Office of the Director, Coordinating
Office for Terrorism Preparedness and
Emergency Response, CDC, 1600 Clifton
Road, NE., Mailstop K72, Atlanta, GA 30333,
Telephone (770) 488–8806.
The Director, Management Analysis and
Services Office, has been delegated the
VerDate Aug<31>2005
19:47 Jul 21, 2008
Jkt 214001
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: July 15, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–16720 Filed 7–21–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Impact of
Cultural and Socioeconomic Factors
on Post-Treatment Surveillance
Among African Americans With
Colorectal Cancer, Potential
Extramural Project (PEP) 2008–R–03.
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting.
Time and Date: 1 p.m.–3 p.m., August 6,
2008 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of ‘‘Impact of Cultural and
Socioeconomic Factors on Post-Treatment
Surveillance among African Americans with
Colorectal Cancer, PEP 2008–R–03.’’
For Further Information Contact: Linda
Shelton, Program Specialist, Coordinating
Center for Health and Information Service,
Office of the Director, CDC, 1600 Clifton
Road, NE., Mailstop E21, Atlanta, GA 30333,
Telephone (404)498–1194. The Director,
Management Analysis and Services Office,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
CDC and the Agency for Toxic Substances
and Disease Registry.
Dated: July 16, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–16721 Filed 7–21–08; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Elimination of
Health Disparities Through Translation
Research (Panel A–1), Funding
Opportunity Announcement (FOA),
CD08–001
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 12:30 p.m.–3:30 p.m.,
August 6, 2008 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the review, discussion, and
evaluation of ‘‘Elimination of Health
Disparities through Translation Research
(Panel A–1), FOA CD08–001.’’
Contact Person for More Information:
Maurine F. Goodman, M.A., M.P.H.,
Scientific Review Administrator, CDC, 1600
Clifton Road, NE., Mailstop D72, Atlanta, GA
30333, Telephone (404) 639–4737.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: July 15, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–16722 Filed 7–21–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Elimination of
Health Disparities Through Translation
Research (Panel D), Funding
Opportunity Announcement (FOA),
CD08–001
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
E:\FR\FM\22JYN1.SGM
22JYN1
Agencies
[Federal Register Volume 73, Number 141 (Tuesday, July 22, 2008)]
[Notices]
[Pages 42575-42576]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-16741]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Roxana Gonzalez, Carnegie Mellon University: Based on reports
submitted by Carnegie Mellon University's (CMU) inquiry and
investigation committees, the Respondent's own admission in sworn
testimony, and additional analysis conducted by the Office of Research
Integrity (ORI) during its oversight review, the U.S. Public Health
Service (PHS) found that Roxana Gonzalez, graduate student, Department
of Social and Decision Sciences and Psychology, CMU, engaged in
scientific misconduct in research supported by National Institute of
Mental Health (NIMH), National Institutes of Health (NIH), grants R01
MH56880, R03 MH62376, and R24 MH67346.
Specifically, PHS found that Ms. Gonzalez engaged in the following
acts of scientific misconduct:
1. Respondent altered the main dependent variable (life events;
life expectation) in the electronic file and the manipulation check
variables for ease-of-thought generation so that the reported study
results are largely unsupported in:
(a) Publication: Lerner, J.S., & Gonzalez, R.M. ``Forecasting one's
future based on fleeting subjective experiences.'' Personality and
Social Psychology Bulletin 31:454-466, 2005;
(b) 2005 Manuscript: Lerner, J. S., & Gonzalez, R. M. ``On
perceiving the self as triumphant when happy or angry'';
(c) Review Article: Lerner J. S., Tiedens, L.Z., & Gonzalez, R. M.
``Portrait of the angry decision maker: How appraisal tendencies shape
anger's influence on cognition.'' Journal of Behavioral Decision
Making: Special Issue on Emotion and Decision Making.
2. Respondent falsified cortisol values, and possibly
cardiovascular measures and optimistic appraisals (as measured by LOT),
so that a large portion of the mediation analyses of Table 3 does not
reflect the data actually collected and analyzed for the study reported
in a publication (Lerner, J.S., Gonzalez, R.M., Dahl, R.E., Hariri,
A.R., & Taylor, S.E. ``Facial expressions of emotion reveal
neuroendocrine and cardiovascular stress responses.'' Biological
Psychiatry 58:743-750, 2005). Respondent further allowed one of her
collaborators to report the results from this study at the Annual
Meeting of the American Psychological Society held in Los Angeles,
California in May 2005, although Respondent's collaborator did not know
at the time that the results were tainted by Respondent's acts of
research misconduct.
3. Respondent falsified the analyses based on participants'
responses to the manipulation check items (including the data for self
reported fear) in a study reported in a publication (Fischhoff, B.,
Gonzalez, R.M., Lerner, J.S., & Small, D.A. ``Evolving judgments of
terrorism's risks: Foresight, hindsight, and emotion.'' Journal of
Experimental Psychology: Applied 11:124-139, 2005.
4. Respondent falsified the main dependent variable (reservation
price, BDM) in the electronic file for 48 of the 175 subjects
participating in a study reported in a 2005 manuscript (Lerner, J.S.,
Gonzalez, R.M., Small, D.A., Lowenstein, G., & Dahl, R.E. ``Emotional
influence on economic behavior among adolescents.''). Respondent
directed the alteration of the paper files for those subjects in order
to match the altered electronic file. One of Respondent's collaborators
included a qualitative description of the results of the research that
is the subject of this study in an NIH grant application, although
Respondent's collaborator did not know at the time that the results
were tainted by the Respondent's acts of research misconduct.
ORI acknowledges Ms. Gonzalez' extensive cooperation with CMU's
research misconduct proceedings.
Ms. Gonzalez has entered into a Voluntary Exclusion Agreement
(Agreement) in which she has voluntarily agreed, beginning on June 26,
2008:
(1) To exclude herself from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant or
contractor to PHS, for a period of three (3) years;
(2) That for a period of three (3) years, any institution that
submits an application for PHS support for a research project on which
the Respondent's participation is proposed or that uses the Respondent
in any capacity on PHS supported research, or that submits a report of
PHS-funded research in which the Respondent is involved, must
concurrently submit a plan for supervision of the Respondent's duties
to the funding agency for approval; the supervisory plan must be
designed to ensure the scientific integrity of the respondent's
research contribution; Respondent agrees to ensure that a copy of the
supervisory plan is also submitted to ORI by the institution;
Respondent agrees that she will not participate in any PHS-supported
research until such a supervisory plan is submitted to ORI;
(3) for a period of three (3) years to ensure that any institution
employing her submits, in conjunction with each application for PHS
funds or report, manuscript, or abstract of PHS-funded research in
which the Respondent is involved, a certification that the data
provided by the Respondent are based on actual experiments or are
otherwise legitimately derived, and that the data, procedures,
analyses, and methodology are accurately reported in the application,
report, manuscript or abstract; the Respondent must ensure
[[Page 42576]]
that the institution sends a copy of the certification to ORI; and
(4) to write ORI-approved letters to (a) collaborators/coauthors of
the manuscripts and published papers cited above, stating what she
falsified/fabricated and offering restitution; and (b) editors of the
journals in which papers were published (even if they have been
retracted/corrected) to state that her falsifications/fabrications were
the underlying reason for the retraction/correction.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E8-16741 Filed 7-21-08; 8:45 am]
BILLING CODE 4150-31-P